SCHEMBL10477669

SCHEMBL10477669

c1ccc(COc2cc(OCc3ccccc3)cc(C3CO3)c2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.50
KMT2A Q03164 1/20 0.50
MAOB P27338 8/20 0.47
TSHR P16473 1/20 0.47
MAOA P21397 3/20 0.46
ALOX5 P09917 1/20 0.46
LMNA P02545 1/20 0.44
CYP1A2 P05177 1/20 0.44
PTGS1 P23219 1/20 0.44
SLC6A2 P23975 1/20 0.44
CYP2C19 P33261 1/20 0.44
PTGS2 P35354 1/20 0.44
SLC6A3 Q01959 1/20 0.44
HIF1A Q16665 1/20 0.44
HDAC6 Q9UBN7 1/20 0.44
GRIN1 Q05586 3/20 0.43
RAB9A P51151 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
GAA P10253 1/20 0.43
MAPT P10636 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9967895 0.90 GRM5 (0.48) MEN1KMT2AMAOBTSHRMAOA
SCHEMBL8190359 0.87 MAOB (0.53) MAOBTSHRMAOAALOX5GRIN1
SCHEMBL8190357 0.87 MAOB (0.53) MAOBTSHRMAOAALOX5GRIN1
SCHEMBL3004785 0.85 LMNA (0.55) MAOBTSHRMAOALMNACYP1A2
SCHEMBL8483583 0.85 LMNA (0.55) MAOBTSHRMAOALMNACYP1A2
SCHEMBL8481310 0.85 LMNA (0.55) MAOBTSHRMAOALMNACYP1A2
SCHEMBL11278270 0.84 CTSV (0.44) MEN1KMT2AMAOBMAOALMNA
SCHEMBL10024632 0.80 TDP1 (0.66) MEN1KMT2AMAOBTSHRMAOA
SCHEMBL4674930 0.80 MEN1 (0.70) MEN1KMT2AMAOBMAOAALOX5
SCHEMBL27081878 0.80 KDM1A (0.49) MAOBTSHRMAOASLC6A2SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10925840-B2 Use of fenoterol and fenoterol analogues in the treatment of glioblastomas and astrocytomas THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2021-02-23 US disclosed
US-20210038540-A1 METHODS OF REGULATING CANNABINOID RECEPTOR ACTIVITY-RELATED DISORDERS AND DISEASES THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICE (US) 2021-02-11 US disclosed
US-10772849-B2 Methods of regulating cannabinoid receptor activity-related disorders and diseases THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2020-09-15 US disclosed
US-20200197332-A1 USE OF FENOTEROL AND FENOTEROL ANALOGUES IN THE TREATMENT OF GLIOBLASTOMAS AND ASTROCYTOMAS THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2020-06-25 US disclosed
US-20200030261-A1 METHODS OF REGULATING CANNABINOID RECEPTOR ACTIVITY-RELATED DISORDERS AND DISEASES THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVIC (US) 2020-01-30 US disclosed
US-20190076379-A1 METHODS OF TREATING BREAST CANCER MITCHELL WOODS PHARMACEUTICALS INC (US) 2019-03-14 US disclosed
US-9908841-B2 Preparation of (R,R)-fenoterol and (R,R)- or (R,S)-fenoterol analogues and their use in treating congestive heart failure THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2018-03-06 US disclosed
US-20180042867-A1 METHODS OF TREATING CANCER MITCHELL WOODS PHARMACEUTICALS INC (US) 2018-02-15 US disclosed
US-20170172945-A1 METHODS OF TREATING BREAST CANCER MITCHELL WOODS PHARMACEUTICALS INC (US) 2017-06-22 US disclosed
US-20170172944-A1 METHODS OF TREATING MELANOMA MITCHELL WOODS PHARMACEUTICALS INC (US) 2017-06-22 US disclosed
US-20170081276-A1 PREPARATION OF (R,R)-FENOTEROL AND (R,R)- OR (R,S)-FENOTEROL ANALOGUES AND THEIR USE IN TREATING CONGESTIVE HEART FAILURE THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV (US) 2017-03-23 US disclosed
US-20100168245-A1 PREPARATION OF (R,R)-FENOTEROL AND (R,R)-OR (R,S)-FENOTEROL ANALOGUES AND THEIR USE IN TREATING CONGESTIVE HEART FAILURE THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES 2010-07-01 US disclosed
US-4853381-A Ethanolamine compounds GLAXO GROUP LIMITED (GB) 1989-08-01 US disclosed
EP-0162576-B1 ETHANOLAMINE COMPOUNDS GLAXO GROUP LIMITED (GB) 1989-07-26 EP disclosed
EP-0162576-A1 Ethanolamine compounds GLAXO GROUP LIMITED (GB) 1985-11-27 EP disclosed
US-4011258-A ETHANOLAMINES AKTIEBOLAGET DRACO (SW) 1977-03-08 US disclosed
US-3937838-A BRONCHODILATORS, DIHYDROXYPHENYL ETHANOLAMINES AKTIEBOLAGET DRACO (SW) 1976-02-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190076379-A1 METHODS OF TREATING BREAST CANCER CNR2, ADRB2, CNR1 MEN1 3975/4885KMT2A 1919/4885MAOB 649/4885
US-20180042867-A1 METHODS OF TREATING CANCER GPR55, ADRB2, GRK2 MEN1 3028/4885KMT2A 1391/4885MAOB 1611/4885
US-20170172945-A1 METHODS OF TREATING BREAST CANCER CNR2, ADRB2, CNR1 MEN1 3975/4885KMT2A 1919/4885MAOB 649/4885
US-20170081276-A1 PREPARATION OF (R,R)-FENOTEROL AND (R,R)- OR (R,S)-FENOTEROL ANALOGUES AND THEIR USE IN TREATING CONGESTIVE HEART FAILURE ADRB2, ADRB1, ADRB3 MEN1 4799/4885KMT2A 4127/4885MAOB 1288/4885
US-20210038540-A1 METHODS OF REGULATING CANNABINOID RECEPTOR ACTIVITY-RELATED DISORDERS AND DISEASES CNR1, CNR2, GPR68 MEN1 2182/4885KMT2A 2950/4885MAOB 1440/4885
US-20170172944-A1 METHODS OF TREATING MELANOMA CNR2, ADRB2, CNR1 MEN1 1723/4885KMT2A 2392/4885MAOB 737/4885
US-20100168245-A1 PREPARATION OF (R,R)-FENOTEROL AND (R,R)-OR (R,S)-FENOTEROL ANALOGUES AND THEIR USE IN TREATING CONGESTIVE HEART FAILURE ADRB2, ADRB1, ADRB3 MEN1 4799/4885KMT2A 4127/4885MAOB 1288/4885
US-20200197332-A1 USE OF FENOTEROL AND FENOTEROL ANALOGUES IN THE TREATMENT OF GLIOBLASTOMAS AND ASTROCYTOMAS ADRB2, ADRB1, ADRA2A MEN1 1082/4885KMT2A 3251/4885MAOB 1275/4885
US-10772849-B2 Methods of regulating cannabinoid receptor activity-related disorders and diseases CNR1, CNR2, GPR68 MEN1 2182/4885KMT2A 2950/4885MAOB 1440/4885
US-10925840-B2 Use of fenoterol and fenoterol analogues in the treatment of glioblastomas and astrocytomas ADRB2, ADRB1, ADRA2A MEN1 1082/4885KMT2A 3251/4885MAOB 1275/4885
US-20200030261-A1 METHODS OF REGULATING CANNABINOID RECEPTOR ACTIVITY-RELATED DISORDERS AND DISEASES CNR1, CNR2, GPR68 MEN1 2182/4885KMT2A 2950/4885MAOB 1440/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.